Biotechnology

ANKE BIO

ANKE BIO released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 541.72 M, actual EPS CNY 0.1

ANKE BIO to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

ANKE BIO released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 683.93 M, actual EPS CNY 0.1103

ANKE BIO released FY2025 earnings on March 30 After-Market (BJT), actual revenue CNY 2.647 B (forecast CNY 3.264 B), actual EPS CNY 0.44 (forecast CNY 0.68)

ANKE BIO to Release FY2025 Earnings on March 31 After-Market (BJT), Forecast Revenue CNY 3.264 B, EPS CNY 0.68

ANKE BIO released FY2025 9 Months Earnings on October 27 After-Market (BJT), Actual Revenue: CNY 1.963 B, Actual EPS: CNY 0.3247

ANKE BIO released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 670.4 M, actual EPS CNY 0.1109

ANKE BIO to Release FY2025 Q3 Earnings Report on October 28 After-Market BJT

ANKE BIO released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 1.292 B, actual EPS CNY 0.2146

ANKE BIO released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 663.43 M, actual EPS CNY 0.0948

ANKE BIO to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Anke Biotechnology's Affiliated Company Submits Application for PA3-17 Injection

Anke Biotech's Subsidiary's PA3-17 Injection Listed as Breakthrough Therapy

Anke Bio Signs Strategic Partnership Agreement With Ascendis Pharma

Anke Biotech Reaches Collaboration with Shanghai Biojoy Pharmaceuticals

Anke Biopharmaceuticals Agents Shengji Pharmaceutical's Long-acting FSH-CTP Fusion Protein

Anke Biotechnology's AK2024 Injection Approved for Clinical Trials

Huansan Securities Researchers Publish Buy Rating Report on Anke Biotechnology

Anke Biotechnology Receives Approval for AK2024 Injection Clinical Trials

Anke Biotechnology Sees Sales Growth in Growth Hormone and 'Ansettin'

300009

On October 28th, ANKE BIO stated during an institutional research that the clinical trial progress of its independently developed "AK2017 Injection" is going smoothly, having completed the enrollment for Phase II clinical trials. It has now submitted a supplementary application for Phase III clinical trials and is expected to initiate Phase III clinical trials at the beginning of next year

Zhitong

ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year

According to the Zhitong Finance APP, ANKE BIO released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.963 billion yuan, a year-on-year increase of 2.15%. The net profit attributable to shareholders of the listed company was 551 million yuan, a year-on-year decrease of 6.48%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 519 million yuan, a year-on-year decrease of 6.56%. The basic earnings per share were 0.3297 yuan

ANKE BIO released its performance for the first three quarters, with a net profit attributable to the parent company of 551 million yuan, a decrease of 6.48%

ANKE BIO held a Phase III clinical trial investigator meeting in Xiamen for two new drugs targeting respiratory viral infections in children, namely AK1012 inhalation solution and human interferon α2b spray. Both products are aimed at common diseases in children, with AK1012 being a modified new formulation designed to treat lower respiratory tract infections caused by respiratory syncytial virus, while the human interferon α2b spray is used for the treatment of herpetic pharyngitis in children

ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections

ANKE BIO announced that it will present the clinical research data of its innovative drug HuA21 at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The study of the drug in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric cancer has shown good anti-tumor activity and safety, supporting the Phase III clinical trial and enhancing the product's market competitiveness

ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting

ANKE BIO presented research results on HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma at the 2025 European Society for Medical Oncology Annual Meeting. The study showed that the objective response rate in the HuA21 group was 80.8%, compared to 76.7% in the control group. A total of 60 patients were enrolled in the study, and the results indicated that HuA21 has good anti-tumor activity

ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%

36Kr learned that ANKE BIO stated on the interactive platform that the company's controlling shareholder does not lend the shares they hold to quantitative institutions

36Kr

ANKE BIO: The company's controlling shareholder does not lend the shares held to quantitative institutions

ANKE BIO announced that its affiliated companies, Boshengji Pharmaceutical Technology Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have been approved by the National Medical Products Administration to conduct the key Phase II clinical trial of PA3-17 injection. This injection is the world's first autologous CAR-T cell therapy product targeting CD7, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies

ANKE BIO: The invested company PA3-17 injection has been approved to enter the critical Phase II clinical trial

ANKE BIO announced that senior management personnel Yao Jianping, holding 6.7622 million shares, accounting for 0.40%, plans to reduce his holdings by no more than 1 million shares, accounting for 0.06% of the company's total share capital, through centralized bidding or block trading from September 26, 2025, to December 25, 2025. The reason for the reduction is personal funding needs, and the shares come from shares issued before the company's initial public offering and the portion of capital reserve converted into share capital

ANKE BIO: Executives plan to reduce holdings by 1 million shares

ANKE BIO announced that the recombinant human follicle-stimulating hormone-CTP fusion protein injection, exclusively represented by Suzhou Shengji Pharmaceutical Co., Ltd. in mainland China and Hong Kong, Macau, and Taiwan, has been approved for marketing by the National Medical Products Administration. This product is the first long-acting recombinant human follicle-stimulating hormone approved in China

ANKE BIO: Exclusive agent product recombinant follicle-stimulating hormone-CTP fusion protein injection approved for market launch

ANKE BIO announced that its operating revenue in the first half of 2025 was 1.292 billion yuan, a year-on-year decrease of 0.51%. Net profit was 367 million yuan, a year-on-year decrease of 11.92%

ANKE BIO(300009.SZ)